AstraZeneca PLC [NASDAQ: AZN] closed the trading session at $53.07 on 10/26/20. The day’s price range saw the stock hit a low of $52.54, while the highest price level was $53.36. The company report on October 23, 2020 that FARXIGA DAPA-CKD Phase III Trial Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients With Chronic Kidney Disease Irrespective of Underlying Cause.
Results reinforce FARXIGA’s potential to treat a wide range of patients with chronic kidney disease.
A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s FARXIGA® (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death in patients with chronic kidney disease (CKD), irrespective of the underlying cause of the disease.1.
The stocks have a year to date performance of 6.44 percent and weekly performance of 1.20 percent. The stock has been moved at 4.12 percent over the last six months. The stock has performed -4.40 percent around the most recent 30 days and changed -5.77 percent over the most recent 3-months.
If compared to the average trading volume of 4.39M shares, AZN reached to a volume of 5998448 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AstraZeneca PLC [AZN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $59.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Berenberg have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 29, 2020. The new note on the price target was released on November 22, 2019, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 1.03, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.45. The Price to Book ratio for the last quarter was 11.39, with the Price to Cash per share for the same quarter was set at 2.32.
AZN stock trade performance evaluation
AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.20. With this latest performance, AZN shares dropped by -4.40% in over the last four-week period, additionally plugging by 4.12% over the last 6 months – not to mention a rise of 11.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 45.54, with the RSI for the last a single of trading hit 48.90, and the three-weeks RSI is set at 46.08 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 54.66, while it was recorded at 52.16 for the last single week of trading, and 51.71 for the last 200 days.
AstraZeneca PLC [AZN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +11.51 and a Gross Margin at +72.35. AstraZeneca PLC’s Net Margin is presently recorded at +5.47.
Return on Total Capital for AZN is now 8.66, given the latest momentum, and Return on Invested Capital for the company is 4.59. Return on Equity for this stock inclined to 10.62, with Return on Assets sitting at 2.23. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 138.85. Additionally, AZN Total Debt to Total Capital is recorded at 58.13, with Total Debt to Total Assets ending up at 29.70. Long-Term Debt to Equity for the company is recorded at 123.54, with the Long-Term Debt to Total Capital now at 51.72.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $14,822 per employee. Receivables Turnover for the company is 4.55 with a Total Asset Turnover recorded at a value of 0.41.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.80.
Earnings per share (EPS) analysis for AstraZeneca PLC [AZN] stock
With the latest financial reports released by the company, AstraZeneca PLC posted 0.5/share EPS, while the average EPS was predicted by analysts to be reported at 0.45/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 19.20%.
AstraZeneca PLC [AZN]: Insider Ownership positions
There are presently around $22,731 million, or 17.60% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 54,544,517, which is approximately -19.023% of the company’s market cap and around 0.50% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 53,661,737 shares of the stock with an approximate value of $2.85 billion in AZN stocks shares; and FMR LLC, currently with $2.53 billion in AZN stock with ownership of nearly -1.083% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 342 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 22,722,805 shares. Additionally, 250 investors decreased positions by around 37,005,886 shares, while 121 investors held positions by with 368,586,891 shares. The mentioned changes placed institutional holdings at 428,315,582 shares, according to the latest SEC report filing. AZN stock had 123 new institutional investments in for a total of 5,078,158 shares, while 41 institutional investors sold positions of 493,764 shares during the same period.